BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1045 related articles for article (PubMed ID: 32194879)

  • 1. Genome-Wide Sequencing for Unexplained Developmental Disabilities or Multiple Congenital Anomalies: A Health Technology Assessment.
    Ontario Health (Quality)
    Ont Health Technol Assess Ser; 2020; 20(11):1-178. PubMed ID: 32194879
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multi-gene Pharmacogenomic Testing That Includes Decision-Support Tools to Guide Medication Selection for Major Depression: A Health Technology Assessment.
    Ontario Health (Quality)
    Ont Health Technol Assess Ser; 2021; 21(13):1-214. PubMed ID: 34484487
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Noninvasive Fetal RhD Blood Group Genotyping: A Health Technology Assessment.
    Ontario Health (Quality)
    Ont Health Technol Assess Ser; 2020; 20(15):1-160. PubMed ID: 33240456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of B-Type Natriuretic Peptide (BNP) and N-Terminal proBNP (NT-proBNP) as Diagnostic Tests in Adults With Suspected Heart Failure: A Health Technology Assessment.
    Ontario Health (Quality)
    Ont Health Technol Assess Ser; 2021; 21(2):1-125. PubMed ID: 34055110
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Carrier Screening Programs for Cystic Fibrosis, Fragile X Syndrome, Hemoglobinopathies and Thalassemia, and Spinal Muscular Atrophy: A Health Technology Assessment.
    Ontario Health (Quality)
    Ont Health Technol Assess Ser; 2023; 23(4):1-398. PubMed ID: 37637488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic Testing for Familial Hypercholesterolemia: Health Technology Assessment.
    Ontario Health (Quality)
    Ont Health Technol Assess Ser; 2022; 22(3):1-155. PubMed ID: 36158868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of genome-wide sequencing for unexplained developmental disabilities and multiple congenital anomalies.
    Li C; Vandersluis S; Holubowich C; Ungar WJ; Goh ES; Boycott KM; Sikich N; Dhalla I; Ng V
    Genet Med; 2021 Mar; 23(3):451-460. PubMed ID: 33110268
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene Expression Profiling Tests for Early-Stage Invasive Breast Cancer: A Health Technology Assessment.
    Ontario Health (Quality)
    Ont Health Technol Assess Ser; 2020; 20(10):1-234. PubMed ID: 32284770
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Placental Growth Factor (PlGF)- Based Biomarker Testing to Help Diagnose Pre-eclampsia in People With Suspected Pre-eclampsia: A Health Technology Assessment.
    Ontario Health (Quality)
    Ont Health Technol Assess Ser; 2023; 23(3):1-146. PubMed ID: 37284279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pre-surgical Nasal Decolonization of
    Ontario Health (Quality)
    Ont Health Technol Assess Ser; 2022; 22(4):1-165. PubMed ID: 36160757
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transcatheter Aortic Valve Implantation in Patients With Severe Aortic Valve Stenosis at Low Surgical Risk: A Health Technology Assessment.
    Ontario Health (Quality)
    Ont Health Technol Assess Ser; 2020; 20(14):1-148. PubMed ID: 33240455
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cell-Free Circulating Tumour DNA Blood Testing to Detect
    Ontario Health (Quality)
    Ont Health Technol Assess Ser; 2020; 20(5):1-176. PubMed ID: 32206157
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Ontario Health (Quality)
    Ont Health Technol Assess Ser; 2021; 21(14):1-186. PubMed ID: 34484488
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular Testing for Thyroid Nodules of Indeterminate Cytology: A Health Technology Assessment.
    Ontario Health (Quality)
    Ont Health Technol Assess Ser; 2022; 22(2):1-111. PubMed ID: 35591972
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bariatric Surgery for Adults With Class I Obesity and Difficult-to-Manage Type 2 Diabetes: A Health Technology Assessment.
    Ontario Health (Quality)
    Ont Health Technol Assess Ser; 2023; 23(8):1-151. PubMed ID: 38130940
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Homologous Recombination Deficiency Testing to Inform Patient Decisions About Niraparib Maintenance Therapy for High-Grade Serous or Endometrioid Epithelial Ovarian Cancer: A Health Technology Assessment.
    Ontario Health (Quality)
    Ont Health Technol Assess Ser; 2023; 23(5):1-188. PubMed ID: 37637244
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intrathecal Drug Delivery Systems for Cancer Pain: A Health Technology Assessment.
    Ontario Health
    Ont Health Technol Assess Ser; 2024; 24(2):1-162. PubMed ID: 38344326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Internet-Delivered Cognitive Behavioural Therapy for Post-traumatic Stress Disorder or Acute Stress Disorder: A Health Technology Assessment.
    Ontario Health (Quality)
    Ont Health Technol Assess Ser; 2021; 21(9):1-120. PubMed ID: 34527087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Skin Substitutes for Adults With Diabetic Foot Ulcers and Venous Leg Ulcers: A Health Technology Assessment.
    Ontario Health (Quality)
    Ont Health Technol Assess Ser; 2021; 21(7):1-165. PubMed ID: 34211616
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 5-Aminolevulinic Acid Hydrochloride (5-ALA)-Guided Surgical Resection of High-Grade Gliomas: A Health Technology Assessment.
    Ontario Health (Quality)
    Ont Health Technol Assess Ser; 2020; 20(9):1-92. PubMed ID: 32194883
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 53.